Yes, in Japan, the Designated Marketing Authorization Holder (DMAH) is responsible for overseeing pharmacovigilance activities. This includes monitoring the safety of pharmaceutical products, reporting adverse events, and ensuring compliance with regulatory requirements. The DMAH collaborates with manufacturers to maintain drug safety and efficacy throughout the product’s lifecycle.